

Dirk Dressler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4125357/publications.pdf>

Version: 2024-02-01

45
papers

1,067
citations

430874

18
h-index

434195

31
g-index

47
all docs

47
docs citations

47
times ranked

842
citing authors

#	ARTICLE	IF	CITATIONS
1	Botulinum toxin therapy: past, present and future developments. <i>Journal of Neural Transmission</i> , 2022, 129, 829-833.	2.8	9
2	Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus. <i>Annals of Physical and Rehabilitation Medicine</i> , 2021, 64, 101376.	2.3	9
3	Botulinum toxin therapy of dystonia. <i>Journal of Neural Transmission</i> , 2021, 128, 531-537.	2.8	14
4	Botulinum toxin dosing in arm muscles: contextual factors. <i>Journal of Neural Transmission</i> , 2021, 128, 315-319.	2.8	2
5	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. <i>Journal of Neural Transmission</i> , 2021, 128, 321-335.	2.8	37
6	OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine. <i>Brain</i> , 2020, 143, e5-e5.	7.6	4
7	Therapeutically relevant features of botulinum toxin drugs. <i>Toxicon</i> , 2020, 175, 64-68.	1.6	10
8	Botulinum toxin therapy in the SARS-CoV-2 pandemic: patient perceptions from a German cohort. <i>Journal of Neural Transmission</i> , 2020, 127, 1271-1274.	2.8	13
9	Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay. <i>Journal of Neural Transmission</i> , 2019, 126, 1625-1629.	2.8	4
10	Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use. <i>Journal of Neural Transmission</i> , 2019, 126, 1337-1340.	2.8	3
11	Do complexing proteins provide mechanical protection for botulinum neurotoxins?. <i>Journal of Neural Transmission</i> , 2019, 126, 1047-1050.	2.8	1
12	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. <i>Journal of Neurology</i> , 2018, 265, 856-862.	3.6	51
13	Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay. <i>Journal of Neural Transmission</i> , 2018, 125, 1351-1354.	2.8	11
14	Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity. <i>Journal of Neural Transmission</i> , 2018, 125, 1481-1486.	2.8	21
15	Botulinum toxin therapy of hemifacial spasm: bilateral injections can reduce facial asymmetry. <i>Journal of Neurology</i> , 2018, 265, 2097-2105.	3.6	13
16	A brief history of neurological botulinum toxin therapy in Germany. <i>Journal of Neural Transmission</i> , 2017, 124, 1217-1221.	2.8	4
17	Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy?. <i>Journal of Neural Transmission</i> , 2017, 124, 1223-1225.	2.8	8
18	Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results. <i>Journal of Neural Transmission</i> , 2017, 124, 253-257.	2.8	17

#	ARTICLE	IF	CITATIONS
19	Immunological aspects of botulinum toxin therapy. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 487-494.	2.8	31
20	Safety of botulinum toxin short interval therapy using incobotulinumtoxin A. <i>Journal of Neural Transmission</i> , 2017, 124, 437-440.	2.8	18
21	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. <i>Journal of Neurology</i> , 2017, 264, 112-120.	3.6	32
22	Reconstituting botulinum toxin drugs: shaking, stirring or what?. <i>Journal of Neural Transmission</i> , 2016, 123, 523-525.	2.8	12
23	Botulinum toxin therapy: reduction of injection site pain by pH normalisation. <i>Journal of Neural Transmission</i> , 2016, 123, 527-531.	2.8	16
24	Botulinum toxin drugs: brief history and outlook. <i>Journal of Neural Transmission</i> , 2016, 123, 277-279.	2.8	39
25	Strategies for treatment of dystonia. <i>Journal of Neural Transmission</i> , 2016, 123, 251-258.	2.8	31
26	Intrathecal Baclofen therapy in Germany: Proceedings of the IAB-Interdisciplinary Working Group for Movement Disorders Consensus Meeting. <i>Journal of Neural Transmission</i> , 2015, 122, 1573-1579.	2.8	24
27	Botulinum toxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures. <i>Journal of Neural Transmission</i> , 2015, 122, 1279-1282.	2.8	10
28	Safety aspects of incobotulinumtoxinA high-dose therapy. <i>Journal of Neural Transmission</i> , 2015, 122, 327-333.	2.8	57
29	Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. <i>Journal of Neural Transmission</i> , 2015, 122, 297-300.	2.8	38
30	An enzyme-linked immunosorbent assay for detection of botulinum toxin-antibodies. <i>Movement Disorders</i> , 2014, 29, 1322-1324.	3.9	13
31	Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®). <i>Journal of Neural Transmission</i> , 2014, 121, 29-31.	2.8	35
32	Brissaud-Sicard syndrome caused by a diffuse brainstem glioma. A rare differential diagnosis of hemifacial spasm. <i>Acta Neurochirurgica</i> , 2014, 156, 429-430.	1.7	5
33	Botulinum toxin in myotonia congenita: it does not help against rigidity and pain. <i>Journal of Neural Transmission</i> , 2014, 121, 531-532.	2.8	3
34	Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. <i>Journal of Neural Transmission</i> , 2014, 121, 367-369.	2.8	12
35	IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®). <i>Journal of Neural Transmission</i> , 2014, 121, 769-771.	2.8	11
36	The Dystonia Discomfort Scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia. <i>European Journal of Neurology</i> , 2014, 21, 459-462.	3.3	11

#	ARTICLE	IF	CITATIONS
37	Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. <i>Journal of Neurology</i> , 2013, 260, 701-713.	3.6	26
38	Towards a dose optimisation of botulinum toxin therapy for axillary hyperhidrosis: comparison of different Botox® doses. <i>Journal of Neural Transmission</i> , 2013, 120, 1565-1567.	2.8	12
39	Interdisziplinärer Arbeitskreis Bewegungsstörungen (IAB): an interdisciplinary working group for promoting multimodal therapy of movement disorders. <i>Journal of Neural Transmission</i> , 2013, 120, 705-710.	2.8	7
40	Clinical applications of botulinum toxin. <i>Current Opinion in Microbiology</i> , 2012, 15, 325-336.	5.1	151
41	Five-year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins. <i>European Journal of Neurology</i> , 2012, 19, 385-389.	3.3	61
42	Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay. <i>Journal of Neural Transmission</i> , 2012, 119, 13-15.	2.8	71
43	Nonprimary dystonias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2011, 100, 513-538.	1.8	24
44	Comparing Botox® and Xeomin® for axillar hyperhidrosis. <i>Journal of Neural Transmission</i> , 2010, 117, 317-319.	2.8	55
45	Subclinical Myasthenia Gravis causing increased sensitivity to botulinum toxin therapy. <i>Journal of Neural Transmission</i> , 2010, 117, 1293-1294.	2.8	24